IP Group's NAV per share rose to 110.4p, taking total NAV to £975.1m, and the stock jumped 9% to 53.5p. The move was driven largely by Pfizer's acquisition of Metsera, a biotech developing obesity treatments, materially improving IP Group's portfolio valuation.
IP Group's NAV per share rose to 110.4p, taking total NAV to £975.1m, and the stock jumped 9% to 53.5p. The move was driven largely by Pfizer's acquisition of Metsera, a biotech developing obesity treatments, materially improving IP Group's portfolio valuation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
